Researchers uncover corneal changes in multiple myeloma patients treated with belantamab mafodotin, revealing potential ...

Researchers use generative AI to design synthetic enhancers that can effectively control gene expression in healthy mammalian ...

As a novel calcineurin inhibitor with proven efficacy in improving renal outcomes, LUPKYNIS addresses a high unmet medical need. With increasing awareness, supportive guidelines, and potential ...

DelveInsight's "LUPKYNIS Market Size, Forecast, and Market Insight Report" highlights the details around LUPKYNIS, the first ...

SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported ...

In this single-arm trial, the median overall survival (OS) observed was 4.0 months (95% CI: 2.5-7.2) among all 64 adults in the primary efficacy analysis based on the Kaplan-Meier estimate. The median ...

Contrary to what textbooks have claimed for over a century, cell division does not always follow the same pattern.

A comprehensive map of aberrant hematopoiesis in people with acute myeloid leukemia defines specific cell states and ...

This study exploring the role of TRPV1 signaling in recruiting macrophages and promoting angiogenesis during tympanic membrane wound healing presents useful findings. However, the strength of evidence ...

Exicure has concluded subject enrolment in its ongoing randomised Phase II trial on GPC-100 (burixafor) in conjunction with ...